Axplora invests Euro 6.5 million to expand production capacity at Vizag site
Axplora has announced a significant investment at its Vizag site in India to expand production capacity and reinforce supply chain resilience. This announcement follows the successful completion of routine USFDA inspections in 2025 at both of Axplora’s Indian manufacturing sites, Vizag and Chennai, which form part of the company’s PharmaZell Business Unit.
The expansion project at Vizag will increase output and create new employment opportunities.
"The investment also advances the company’s sustainability goals by supporting efficient, vertically integrated production at a single site," the release stated.
“This investment reflects Axplora’s strategic commitment to operational excellence and customer- centric growth,” said Martin Meeson, CEO of Axplora. “By strengthening our infrastructure in Vizag, we are enhancing our ability to deliver high-quality, reliable, and scalable solutions to customers worldwide.”
Both the Vizag and Chennai sites successfully completed routine inspections by the US Food and Drug Administration (USFDA) in 2025, each concluding with a Voluntary Action Indicated (VAI) classification.
As per the release, the inspector at the Chennai facility highlighted several areas of excellence, including the strong and consistent implementation of current Good Manufacturing Practices (cGMP), streamlined and efficient document management and retrieval processes, and the high standards maintained in facility upkeep and overall site hygiene.
“These results are a powerful validation of our team’s diligence and our unwavering focus on quality.” said Anant Barbadikar, Co-President of PharmaZell and Chief Operating Officer in India. “The success of both inspections reflects not just regulatory compliance, but the operational integrity and continuous improvement culture we strive to embed across every Axplora site.”
Axplora is a manufacturing partner to over 900 of the world’s pharmaceutical and biotech companies, formed from the integration of PharmaZell, Farmabios, and Novasep CDMO.
Axplora supports pharmaceutical and biotech companies in developing and producing life-changing therapies. Axplora operates 9 API manufacturing sites across Europe and India, providing multi-site capacity to partners worldwide.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.